Simultaneous Modulation of Multidrug Resistance and Antiapoptotic Cellular Defense by MDR1 and BCL-2 Targeted Antisense Oligonucleotides Enhances the Anticancer Efficacy of Doxorubicin (original) (raw)

Abstract

Purpose. To enhance the anticancer efficacy of an established drug by the simultaneous suppression of pump and nonpump cellular resistance.

Methods. Multidrug resistant human ovarian (A2780/AD) and breast (MCF-7/AD) cancer cells were used. Doxorubicin (DOX) and antisense oligonucleotides (ASO) targeted to MDR1 and BCL-2 mRNA were combined in a solution within one liposomal drug delivery system (LDDS) in different combination series. Ten series of experiments were performed. In each series cells were incubated with 12 to 45 concentrations of free DOX and different liposomal formulations over a period of 6 to 48 h. Cytotoxicity, apoptosis induction, caspases, MDR1, BCL-2, and APAF-1 genes, P-glycoprotein, and BCL-2 protein were studied.

Results. The combination of DOX and ASO targeted to MDR1 and BCL-2 mRNA in one LDDS exhibited a dramatic increase in the anticancer action of DOX. As a result of the simultaneous suppression of pump and nonpump cellular resistance by the inhibition of P-glycoprotein and BCL-2 protein synthesis, a significant increase in the activation of caspases and apoptosis was observed.

Conclusions. The simultaneous suppression of multidrug resistance and antiapoptotic cellular defense significantly enhanced the anticancer activity of DOX. Therefore, the proposed DDS combination may potentially be used in the treatment of multidrug-resistant ovarian and breast cancers.

Access this article

Log in via an institution

Subscribe and save

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

REFERENCES

  1. T. Minko, P. Kopeckova, and J. Kopecek. Chronic exposure to HPMA copolymer bound adriamycin does not induce multidrug resistance in a human ovarian carcinoma cell line. J. Control. Release 59:133-148 (1999).
    Google Scholar
  2. T. Minko, S. S. Dharap, R. I. Pakunlu, and J. L. Colaizzi. Advanced drug delivery systems in cancer chemotherapy. Dis. Management Clin. Outcomes 3:48-54 (2001).
    Google Scholar
  3. M. M. Gottesman, T. Fojo, and S. E. Bates. Multidrug resistance in cancer: role of ATP-dependent transporters. Nature Rev. Cancer 2:48-58 (2002).
    Google Scholar
  4. J. Kvackajova-Kisucka, M. Barancik, and A. Breier. Drug transporters and their role in multidrug resistance of neoplastic cells. Gen. Physiol. Biophys. 20:215-237 (2001).
    Google Scholar
  5. T. Minko, P. Kopeckova, and J. Kopecek. Comparison of the anticancer effect of free and HPMA copolymer-bound adriamycin in human ovarian carcinoma cells. Pharm. Res. 16:986-996 (1999).
    Google Scholar
  6. T. Minko, P. Kopeckova, and J. Kopecek. Efficacy of the chemotherapeutic action of HPMA copolymer-bound doxorubicin in a solid tumor model of ovarian carcinoma. Int. J. Cancer 86:108-117 (2000).
    Google Scholar
  7. T. Minko, P. Kopeckova, and J. Kopecek. Preliminary evaluation of caspase-dependent apoptosis signaling pathways of free and HPMA copolymer-bound doxorubicin in human ovarian carcinoma cells. J. Control. Release 71:227-237 (2001).
    Google Scholar
  8. S. K. Alahari, R. DeLong, M. H. Fisher, N. M. Dean, P. Viliet, and R. L. Juliano. Novel chemically modified oligonucleotides provide potent inhibition of P-glycoprotein expression. J. Pharmacol. Exp. Ther. 286:419-428 (1998).
    Google Scholar
  9. M. V Corrias and G. P. Tonini. An oligomer complementary to the 5′ end #x00AEion of MDR1 gene decreases resistance to doxorubicin of human adenocarcinoma-resistant cells. Anticancer Res. 12:1431-1438 (1992).
    Google Scholar
  10. E. V. Kostenko, P. P. Laktionov, V. V. Vlassov, and M. A. Zenkova. Down#x00AEulation of PGY1/MDR1 mRNA level in human KB cells by antisense oligonucleotide conjugates. RNA accessibility in vitro and intracellular antisense activity. Bio#x03A7;m. Biophys. Acta 1576:143-147 (2002).
    Google Scholar
  11. S. Motomura, T. Motoji, M. Takanashi, Y. H. Wang, H. Shiozaki, I. Sugawara, E. Aikawa, A. Tomida, T. Tsuruo, N. Kanda, and H. Mizogu#x03A7;. Inhibition of P-glycoprotein and recovery of drug sensitivity of human acute leukemic blast cells by multidrug resistance gene (mdr1) antisense oligonucleotides. Blood 91:3163-3171 (1998).
    Google Scholar
  12. A. V. Kabanov and V. Y. Alakhov. Pluronic block copolymers in drug delivery: from micellar nanocontainers to biological response modifiers. Crit. Rev. Ther. Drug Carrier Syst. 19:1-72 (2002).
    Google Scholar
  13. A. Gross, J. M. McDonnell, and S. Korsmeyer. BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 13:1899-1911 (1999).
    Google Scholar
  14. J. Reed. Dys#x00AEulation of apoptosis in cancer. J. Clin. Oncol. 17:2941-2953 (1999).
    Google Scholar
  15. V. Poulaki, N. Mitsiades, M. E. Romero, and M. Tsokos. Fas-mediated apoptosis in neuroblastoma requires mitochondrial activation and is inhibited by FLICE inhibitor protein and bcl-2. Cancer Res. 61:4864-4872 (2001).
    Google Scholar
  16. D. E. L. de Mendes, N. Hudon, N. McIntosh, and L. D. Mayer. Molecular and pharmacokinetics properties associated with the therapeutics of Bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin. Clin. Cancer Res. 6:2891-2902 (2000).
    Google Scholar
  17. M. Konopleva, A. M. Tari, Z. Estrov, D. Harris, Z. Xie, S. Zhao, G. Lopez-Berestein, and M. Andreeff. Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins. Blood 15:3929-3938 (2000).
    Google Scholar
  18. T. Minko, A. Stefanov, and V. Pozharov. Lung hypoxia: Antioxidant and antiapoptotic effects of liposomal #x0386 tocopherol. J. Appl. Physiol. 93:1550-1560 (2002).
    Google Scholar
  19. T. Minko, P. Kopeckova, V. Pozharov, and J. Kopecek. HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line. J. Control. Release 54:223-233 (1998).
    Google Scholar
  20. T. Minko, P. Paranjpe, B. Qiu, A. Lalloo, R. Won, S. Stein, and P. J. Sinko. Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethylene glycol) conjugates in sensitive and multidrug resistant human ovarian carcinoma cells. Cancer Chemother. Pharm. 50:143-150 (2002).
    Google Scholar

Download references

Author information

Authors and Affiliations

  1. Department of Pharmaceutics, Rutgers, The State University of New Jersey, Piscataway, New Jersey, 08854
    Refika I. Pakunlu, Thomas J. Cook & Tamara Minko
  2. Cancer Institute of New Jersey, New Brunswick, New Jersey
    Tamara Minko

Authors

  1. Refika I. Pakunlu
    You can also search for this author inPubMed Google Scholar
  2. Thomas J. Cook
    You can also search for this author inPubMed Google Scholar
  3. Tamara Minko
    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence toTamara Minko.

Rights and permissions

About this article

Cite this article

Pakunlu, R.I., Cook, T.J. & Minko, T. Simultaneous Modulation of Multidrug Resistance and Antiapoptotic Cellular Defense by MDR1 and BCL-2 Targeted Antisense Oligonucleotides Enhances the Anticancer Efficacy of Doxorubicin.Pharm Res 20, 351–359 (2003). https://doi.org/10.1023/A:1022687617318

Download citation